Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration

Ophthalmology - Netherlands
doi 10.1016/j.ophtha.2013.10.037
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Elsevier BV

Related search

Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration

European Ophthalmic Review
2012English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2013English

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Journal of Clinical & Experimental Ophthalmology
2012English

Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up

Clinical Ophthalmology
Ophthalmology
2016English

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Archives of Ophthalmology
2007English

PSS10 Cost- Effectiveness of Ranibizumab in Patients With Neovascular Wet Age-Related Macular Degeneration (Namd) at the Mexican Social Security System (Imss)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology
Ophthalmology
2016English

Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy